---
layout: post
title: New Drug Approvals 2014 - Pt. XIV - Miltefosine (Impavido ™)
date: '2015-02-04T15:37:00.000Z'
author: Gerard JP van Westen
tags: 
modified_time: '2015-02-04T15:37:14.285Z'
thumbnail: http://4.bp.blogspot.com/--hJr1OlW3WU/VNHd17iXhxI/AAAAAAAAVKE/GsFl3XK4FmQ/s72-c/impavido.jpg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-8241219854316599768
blogger_orig_url: https://www.blogger.com/comment.g?blogID=2546008714740235720&postID=8241219854316599768
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/--hJr1OlW3WU/VNHd17iXhxI/AAAAAAAAVKE/GsFl3XK4FmQ/s1600/impavido.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/--hJr1OlW3WU/VNHd17iXhxI/AAAAAAAAVKE/GsFl3XK4FmQ/s1600/impavido.jpg" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,1,1,0,1,0,0,1,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="41" src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/1,1,1,1,0,1,0,0,1,1" width="400" /></a></div>
<div style="text-align: center;">
<b><br />
</b><b>ATC Code:&nbsp;</b><a href="http://www.whocc.no/atc_ddd_index/?code=L01XX09">L01XX09</a></div>
<div style="text-align: center;">
<b>Wikipedia:</b>&nbsp;<a href="http://en.wikipedia.org/wiki/Miltefosine">Miltefosine</a></div>
<div style="text-align: center;">
<b>ChEMBL:&nbsp;</b><a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL125">CHEMBL125</a></div>
<br />
On March 19th the&nbsp;<a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm389671.htm">FDA approved</a>&nbsp;<a href="http://en.wikipedia.org/wiki/Miltefosine">&nbsp;Miltefosine</a>&nbsp;(Impavido ™) for the treatment of&nbsp;a tropical disease called leishmaniasis, specifically patients 12 years of age or older. The drug is the first approved drug for treatment of cutaneous of mucosal leishmaniasis.<br />
<br />
<a href="http://www.who.int/mediacentre/factsheets/fs375/en/">Leishmaniasis </a>is caused by protozoan parasites of the genus <a href="http://en.wikipedia.org/wiki/Leishmania">Leishmania</a>, infection is usually by bites of certain types of sandflies. Subsequently the disease can manifest itself in three ways:&nbsp;cutaneous, mucocutaneous, or visceral leishmaniasis.<br />
<br />
<b>Target(s)</b><br />
The working mechanism of Miltefosine against Leishmaniasis is currently unknown. However it is thought that the <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204684s000lbl.pdf">mechanism of action</a> involves interaction with lipids (phospholipids and sterols, also membrane lipids). Furthermore it is thought to interact with cytochrome c oxidase (hence interfering with mitochondrial function) and cause an apoptosis like cell death.<br />
<b><br /></b>
Miltefosine is also under investigation as an HIV inhibitor, here it targets <a href="http://en.wikipedia.org/wiki/Protein_kinase_B#AKT_Inhibitors">protein Kinase B </a>and hence is an AKT inhibitor&nbsp;(Uniprot <a href="http://www.uniprot.org/uniprot/P31749">P31749</a>; PDB <a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=3MV5">3MV5</a>). <span style="color: red;">&nbsp;</span><br />
<div>
<br /></div>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-OJgKNgXesl0/VNHefOrqD-I/AAAAAAAAVKM/EbgNTaUIZKE/s1600/Screen%2BShot%2B2015-02-04%2Bat%2B09.55.11.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/-OJgKNgXesl0/VNHefOrqD-I/AAAAAAAAVKM/EbgNTaUIZKE/s1600/Screen%2BShot%2B2015-02-04%2Bat%2B09.55.11.png" height="112" width="640" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<div class="separator" style="clear: both;">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<span style="text-align: left;">Miltefosine (</span><a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL125">CHEMBL125</a>;&nbsp;<span style="text-align: left;">Pubchem : <a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3599">3599</a></span><span style="text-align: left;">) is a small molecule drug with a molecular weight of 407.6 Da, an AlogP of 3.72, 20 rotatable bonds, and no rule of 5 violations.&nbsp;</span></div>
<div class="separator" style="clear: both; text-align: center;">
<br /></div>
<b>Canonical SMILES</b>:&nbsp;CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C<br />
<b>InChi</b>:&nbsp;InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3<br />
<div>
<b>Standard InChI Key:&nbsp;</b>PQLXHQMOHUQAKB-UHFFFAOYSA-N</div>
<div>
<br />
</div>
<div>
<b>Dosage</b></div>
<div>
The recommended dose of Miltefosine is twice daily 50 mg (breakfast and dinner) for patients 33-44 kg and three times daily 50 mg (breakfast, lunch, dinner) for patients 45 kg or greater. Administration is recommended with food and treatement lasts 28 consecutive days.&nbsp;</div>
<div>
<span style="color: red;"><br />
</span></div>
<div>
<div style="display: inline !important;">
<b>Warning / limitations of use</b></div>
</div>
<div>
<div style="display: inline !important;">
<div>
<a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204684s000lbl.pdf">A summary of warnings and limitations is given, for a full overview see the prescribing information.</a><br />
<i><br /></i>
<i>Embryo-Fetal Toxicity</i><br />
Miltefosine may cause fetal harm and usage is contraindicated in women. A pregnancy test is recommended prior to prescribing.<br />
<br />
<i>Sjogren-Larsson-Syndrome</i><br />
Miltefosine is contraindicated in patients with&nbsp;<a href="http://en.wikipedia.org/wiki/Sj%C3%B6gren%E2%80%93Larsson_syndrome">Sjögren-Larsson-Syndrome</a>,&nbsp;an autosomal recessive form of ichthyosis apparent at birth.<br />
<br />
<i>Reproductive effects</i><br />
Miltefosine caused impaired fertility in female rats (1.0 times maximum recommended human dose (MRHD)) and a reduced viable sperm count and impaired fertility in male rats&nbsp;(0.4 times MRHD). Higher doses (1.0 MRHD) caused testicular atrophy, and non-fully-reversible (10 weeks after administration) impaired fertility. <br />
<br />
In female dogs Miltefosine caused reversible follicular atresia and diestrus at 0.2 times MRHD.<br />
<br />
Finally, scrotal pain and decreased or absent ejaculation has been reported during therapy.<br />
<br />
<i>Renal effects</i><br />
Elevations of serum Creatine were noted in clinical trials and renal function monitoring is recommended.<br />
<br />
<i>Hepatic effects</i><br />
Elevations in liver transaminase and biluribin were noted in trials, monitoring is recommended during therapy.<br />
<i><br /></i>
<i>Gastrointestinal effects</i><br />
Vomiting and / or diarrhea have commonly occur during treatment, fluid intake encouragement is recommended.<br />
<i><br /></i>
<i>Thrombocytopenia</i><br />
Thrombocytopenia during therapy has been reported in patients treated for visceral leishmaniasis. Platelet count monitoring during therapy is recommended for visceral leishmaniasis.<br />
<br />
<i>Stevens-Johnson Syndrome</i><br />
Stevens-Johnson Syndrome has been reported during treatment. Discontinuation is recommended upon observing exfoiative or bullous rash.</div>
<div>
<br />
<br />
<b>Pharmacokinetics</b></div>
<div>
Miltefosine has a very long half-life (&gt; 6 days), hence at the end of the 28 day treatment, steady state concentrations have not been reached.<br />
<br /></div>
<div>
<i>Metabolism</i></div>
<div>
No in vitro oxidative metabolism by 15 different human cytochrome P450 enzymes (1A1, 1A2,&nbsp;1B1, 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 2D6, 2E1, 3A4, 3A5, 3A7, and 4A1) was observed.<br />
<br />
A slow metabolic breakdown could be shown in human hepatocytes, resulting in the release of&nbsp;choline by phospholipase D-like cleavage of the miltefosine molecule. The fatty alcohol containing&nbsp;fragment of miltefosine can enter the metabolism of fatty acids after being oxidized to&nbsp;palmitic acid. This oxidation is blocked in patients with Sjögren-Larsson syndrome, which is&nbsp;caused by a genetic defect in fatty aldehyde dehydrogenase activity.&nbsp;</div>
<div>
<span style="color: red;"><br />
</span></div>
<div>
<b>License holder</b></div>
<div>
The license holder is&nbsp;<a href="http://www.gud-knight.com/en/knight-therapeutics-inc-announces-fda-approval-for-impavido-miltefosine-for-the-treatment-of-visceral-mucosal-and-cutaneous-leishmaniasis-awarded-priority-review-voucher">Knight Therapeutics</a>, the highlights of the prescribing information can be found&nbsp;<a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204684s000lbl.pdf">here</a>.</div>
<div>
<br /></div>
<div style="font-weight: bold;">
</div>
</div>
</div>
</div>
